Cont
C1

5. (Amended) The method of claim 4, wherein the tumor is ductal carcinoma *in situ* or lobular carcinoma *in situ*.

6. (Amended) The method of claim 1, wherein the tumor is an invasive carcinoma.

Sub
B1

7. (Amended) The method of claim 6, wherein the tumor is tubular or lobular invasive carcinoma.

8. (Amended) The method of claim 2, wherein the clinically manifest mammary tumor is a metastatic mammary tumor.

9. (Amended) The method of claim 1, wherein the medicament is for the treatment or prevention of mammary tumors in premenopausal or postmenopausal women.

10. (Amended) The method of claim 1, wherein the medicamentis used in combination with at least one other cancer therapy.

11. (Amended) The method of claim 10, wherein the other cancer therapy is surgery or chemotherapy.

12. (Amended) The method of claim 1, wherein the mammary tumors comprise cells that are estrogen receptor-positive.

13. (Amended) The method of claim 12, wherein the medicament is used in combination with an antiestrogen.

14. (Amended) The method of claim 13 , wherein the medicament is used simultaneously, sequentially or separately with the antiestrogen.

15. (Amended) The method of claim 13, wherein the antiestrogen is Tamoxifen.

16. (Amended) The method of claim 15, wherein Tamoxifen is administered orally in a daily amount of about 30 milligrams.

17. (Amended) The method of claim 1, wherein the medicament comprises an amount of hCG that enables administration of 100 to 20,000 IU of hCG to a patient per day.

18. (Amended) The method of claim 1, wherein the medicament comprises an amount of hCG that enables administration of 50 to 50,000 micrograms of hCG to a patient per day.

19. (Amended) The method of claim 18, wherein hCG is administered in an amount of 250 to 3,000 micrograms per day.

20. (Amended) The method of claim 1, wherein the medicament is formulated to enable administration thereof every second day.

21. (Amended) The method of claim 1, wherein the medicament is formulated to enable administration thereof three times a week.

22. (Amended) The method of claim 1, wherein the medicament is formulated to enable administration thereof for several weeks.

23. (Amended) The method of claim 22, wherein the medicament is administered for at least 12 weeks.

24. (Amended) The method of claim 1, wherein the medicament is formulated for subcutaneous administration.

25. (Amended) The method of claim 13, wherein the medicament is used in combination with Type 1 interferon and the antiestrogen.

26. (Amended) The method of claim 1, wherein the hCG is recombinant hCG.

27. (Amended) The method of claim 1, wherein the hCG is replaced by a protein having the biological activity of hCG or a binding activity toward a hCG receptor.

28. (Amended) The method of claim 27, wherein the protein is selected from the group consisting of LH, recombinant LH, LH fusion molecule, TSH fusion molecules and FSH fusion molecules.

30. (Amended) The pharmaceutical composition of claim 29, formulated for administration of the hCG in an amount of 100 to 20,000 IU to a patient per day.

31. (Amended) The pharmaceutical composition of claim 29, formulated for administration of the hCG in an amount of 50 to 50,000 micrograms to a patient per day.

32. (Amended) The pharmaceutical composition of claim 31, wherein the hCG is administered in an amount of 250 to 3,000 micrograms per day.

33. (Amended) The pharmaceutical composition of claim 29, formulated for administration every second day.

34. (Amended) The pharmaceutical composition of claim 29, formulated for administration three times a week.

35. (Amended) The pharmaceutical composition of claim 29, formulated for administration for several weeks.

36. (Amended) The pharmaceutical composition of claim 29, formulated for administration for at least 12 weeks.

37. (Amended) The pharmaceutical composition of claim 29, formulated for subcutaneous administration.

38. (Amended) The pharmaceutical composition of claim 29, which is used simultaneously, sequentially or separately with an antiestrogen.

41. (Amended) The pharmaceutical composition of claim 38, which is used in combination with a Type 1 interferon.

42. (Amended) The pharmaceutical composition of claim 29, wherein hCG is recombinant hCG.

43. (Amended) The pharmaceutical composition of claim 29, wherein hCG is replaced by a protein having the biological activity of hCG and/or a binding activity toward the hCG receptor.

45. (Amended) A method of treating or preventing mammary tumors, comprising administering a host in need thereof an amount of hCG effective to inhibit proliferation of mammary tumor cells.

Cancel claims 46-52.

53. (Amended) An article of manufacture comprising a container, in which is contained a pharmaceutical composition according to claim 29, and which comprises a label stating the use of the pharmaceutical composition for the treatment of breast cancer.

Add the following new claims:

54. (New) The method of claim 45, wherein the mammary tumor is a clinically manifest mammary tumor.

55. (New) The method of claim 54, wherein the clinically manifest mammary tumor is a primary tumor.

56. (New) The method of claim 45, wherein the mammary tumor is a non-invasive carcinoma.

57. (New) The method of claim 56, wherein the carcinoma is ductal carcinoma *in situ* or lobular carcinoma *in situ*.

58. (New) The method of claim 45, wherein the mammary tumor is an invasive carcinoma.

59. (New) The method of claim 58, wherein the carcinoma is tubular or lobular invasive carcinoma.

60. (New) The method of claim 54, wherein the clinically manifest mammary tumor is a metastatic mammary tumor.

61. (New) The method of claim 45, wherein the host is a premenopausal woman.

62. (New) The method of claim 45, wherein the host is a postmenopausal woman.

63. (New) The method of claim 45, combined with at least one other cancer therapy.

64. (New) The method of claim 63, wherein the at least one other cancer therapy is surgery or chemotherapy.

65. (New) The method of claim 45, wherein the mammary tumors comprise cells that are estrogen receptor-positive.

66. (New) The method of claim 64, wherein the hCG is administered in combination with an antiestrogen.

67. (New) The method of claim 66, wherein the hCG is administered simultaneously, sequentially or separately with the antiestrogen.

68. (New) The method of claim 66, wherein the antiestrogen is Tamoxifen.

69. (New) The method of claim 68, wherein the Tamoxifen is administered orally in a daily amount of about 30 milligrams.

70. (New) The method of claim 45, wherein the hCG is administered in an amount of 100 to 20,000 IU per day.

71. (New) The method of claim 45, wherein the hCG is administered in amount of 50 to 50,000 micrograms per day.

72. (New) The method of claim 71, wherein the hCG is administered in an amount of 250 to 3,000 micrograms per day.

73. (New) The method of claim 45, wherein the hCG is administered every second day.

74. (New) The method of claim 45, wherein the hCG is administered three times each week.

75. (New) The method of claim 45, wherein the hCG is administered for several weeks.

76. (New) The method of claim 75, wherein the hCG is administered for at least 12 weeks.

77. (New) The method of claim 45, wherein the hCG is administered subcutaneously.

78. (New) The method of claim 45, wherein the hCG is administered in combination with Type 1 interferon.

79. The method of claim 78, wherein the hCG and Type 1 interferon are administered in combination with an antiestrogen.

80. (New) The method of claim 45, wherein the hCG is recombinant hCG.

81. (New) The method of claim 45, wherein the hCG is replaced by a protein having the biological activity of hCG or a binding activity toward a hCG receptor.

82. (New) The method of claim 81, wherein the protein is selected from the group consisting of LH, recombinant LH, LH fusion molecule, TSH fusion molecules and FSH fusion molecules.

83. (New) A pharmaceutical composition for the treatment of breast cancer comprising a pharmaceutically active amount of hCG and a pharmaceutically active amount of an antiestrogen, in the presence of one or more pharmaceutically acceptable excipients.

84. (New) The pharmaceutical composition of claim 83, formulated for administration of the hCG to a patient in an amount of 100 to 20,000 IU per day.

85. (New) The pharmaceutical composition of claim 83, formulated for administration of the hCG to a patient in an amount of 50 to 50,000 micrograms per day.

86. (New) The pharmaceutical composition of 85, wherein the hCG is administered to the patient in an amount of 250 to 3,000 micrograms per day.

87. (New) The pharmaceutical composition of claim 83, wherein the hCG is recombinant hCG.

88. (New) The pharmaceutical composition of claim 83, wherein the antiestrogen is Tamoxifen.

89. (New) The pharmaceutical composition of claim 83, formulated for use in combination with a Type 1 interferon.

90. (New) The pharmaceutical composition of claim 83, formulated for subcutaneous administration.

91. (New) An article of manufacture comprising a container, in which is contained:

a) the pharmaceutical composition of claim 29; and

b) an antiestrogen;

and which comprises a label stating the use of the pharmaceutical composition and the antiestrogen, together or separately, for the treatment of breast cancer.

92. (New) The article of manufacture of claim 91, wherein the antiestrogen is Tamoxifen.

93. (New) The article of manufacture of claim 92, wherein the Tamoxifen formulated for oral administration in a daily amount of about 30 milligrams.

94. The article of manufacture of claim 91, which further comprises a Type 1 interferon, wherein the label further states the use of the pharmaceutical composition, the antiestrogen and the Type 1 interferon, together or separately, for the treatment of breast cancer.

95. (New) A method of treating or preventing mammary tumors, wherein the tumors comprise cells that are estrogen receptor-positive, the method comprising administering a host in need thereof an amount of hCG effective to inhibit proliferation of mammary tumor cells, wherein the hCG is administered in combination with an antiestrogen.

96. (New) The method of claim 95, wherein the hCG is administered simultaneously, sequentially or separately with the antiestrogen.

97. (New) The method of claim 95, wherein the antiestrogen is Tamoxifen.

98. (New) The method of claim 97, wherein the Tamoxifen is administered orally in a daily amount of about 30 milligrams.

99. (New) The method of claim 95, wherein the hCG is administered in amount of 50 to 50,000 micrograms per day.

100. (New) The method of claim 95, wherein the hCG is administered every second day or three times each week.

101. (New) The method of claim 95, wherein the hCG is administered for several weeks.

102. (New) The method of claim 95, wherein the hCG is administered subcutaneously.

103. (New) The method of claim 95, wherein the hCG and antiestrogen are administered in combination with Type 1 interferon.